Last reviewed · How we verify
MyoCell™ Autologous Myoblasts
MyoCell™ Autologous Myoblasts is a Small molecule drug developed by Bioheart, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | MyoCell™ Autologous Myoblasts |
|---|---|
| Sponsor | Bioheart, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MYOHEART™ (Myogenesis Heart Efficiency and Regeneration Trial) (PHASE1)
- Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MyoCell™ Autologous Myoblasts CI brief — competitive landscape report
- MyoCell™ Autologous Myoblasts updates RSS · CI watch RSS
- Bioheart, Inc. portfolio CI
Frequently asked questions about MyoCell™ Autologous Myoblasts
What is MyoCell™ Autologous Myoblasts?
MyoCell™ Autologous Myoblasts is a Small molecule drug developed by Bioheart, Inc..
Who makes MyoCell™ Autologous Myoblasts?
MyoCell™ Autologous Myoblasts is developed by Bioheart, Inc. (see full Bioheart, Inc. pipeline at /company/bioheart-inc).
What development phase is MyoCell™ Autologous Myoblasts in?
MyoCell™ Autologous Myoblasts is in Phase 1.
Related
- Manufacturer: Bioheart, Inc. — full pipeline
- Compare: MyoCell™ Autologous Myoblasts vs similar drugs
- Pricing: MyoCell™ Autologous Myoblasts cost, discount & access